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Abstract: 
Gaucher  disease  is the autosomally recessively inherited deficiency of the lysosomal enzyme 
glucocerebrosidase. Increasing storage of glucocerebrosides leads to a multisystem disease, the prevalence of 
which is about 1 : 40,000 in central Europe and up to 1 : 2,000 in some other countries (e. g. Israel). The acute 
and chronic neuronopathic forms of the disease (formerly defined as Gaucher types 2 and 3) account for only 5 
to 10% of all Gaucher patients in Central Europe and Germany and are thus less frequent than the non-
neuronopathic disease (formerly defined as Gaucher type 1). Gaucher's disease is usually associated with spleno- 
and hepatomegaly, fatigue, skeletal complications, and several corresponding hematological and laboratory 
abnormalities. In 5 to 10% of the patients there are also central nervous symptoms such as myoclonic seizures, 
oculomotoric apraxia and a slight mental retardation.     Recent epidemiological data indicate that only 10 to 
20% of all Gaucher patients are correctly diagnosed (and treated) in Germany. The diagnosis today can be done 
in all patients by noninvasive methods, i. e. determination of the glucocerebrosidase activity in peripheral 
leukocytes and of the genetic defect, in this research the PCR technique was used to analyze the mutation in 
glucocerebrosidases gene (G ---C). 
Key words:  Gaucher disease (GD), lysosomal storage disorder (LSD),lysosomal enzyme glucocerebrosidase, 
PCR, Mutation.    
 
1- Introduction: 
Gaucher disease (GD) is the most common pan-ethnic inherited lysosomal storage disorder (LSD) (Beutler 
& Grabowski , 2001). The accumulation of glucocerebroside in the lysosomes of macrophages results from 
inherited deficiency of lysosomal acid beta-glucosidase due to mutations in the GBA1 gene which is located on 
chromosome 1q21(Brady, 1966, Beutler & Grabowski , 2001),the disease usually seen in closed communities 
like in Ashkenazi Jews, Approximately 300 mutations, mostly autosomal recessive, have been described,  the 
predominant point mutation is N370S. This mutation accounts for about75% of the mutant alleles in 
Jewishpatients and about 30% in non-Jewish patients.  Approximately 300 mutations, mostly autosomal 
recessive, have been described(Koprivica et al. 2000, Horowitz , et al.( 1998).  
The L444P mutation is common in the Norrbottnian population, and the homozygous 
state has a very high association with the neuronopathicvariants of GD(Jmoudiak & Futerman , 2005 Beutler  et 
al. 1993).  
 
There are three types of GD:  
1- Type 1 (non-neuronopathic): constitutes 94% of all cases and is usually considered to be non-
neuronopathic. The onset of the disease may occur at any age.  
2- Type 2  (acute neuronopathic): the onset is in infancy (socalled neuronopathic infantile, cerebral, or 
perinatal lethal GD) and, accounts for 1% of all GD. It is characterised by a short life expectancy of 2-3 
years or less due to severe neurological consequences related to the disease.   
3- Type 3  (chronic neuronopathic): presents in early childhood and accounts for approximately 5% of all 
patients. The range of neurological involvement in this group is quite broad. 
 The non-neuronopathic is the most common type (93 %) in the Western world and is distinguished from the 
other types by the lack of primary central nervous system involvement (Grabowski et al. 2012,CMS 2015, 
Poll et al. 2000, Kallish & Kaplan 2013). 
Gaucher disease is characterized by varying degrees of splenomegaly and hepatomegaly, anemia, 
thrombocytopenia, skeletal lesions, and bone pain. Types 2 and 3 are both rare, with acute and fulminating (type 
2), or heterogeneous and attenuated (type 3) neurological involvement accompanying visceral 
manifestations(Goker-Alpan et al. 2003).  
the chronic stimulation of the immune system by accumulated glucocerebroside, or by hyper secretion of 
cytokines by Gaucher cells may leads to  malignant changes (e.g. multiple myeloma, lymphomas, chronic 
lymphatic leukemia) are not uncommon(Brautbar et al. 2004, Shiarn et al. 1993). 
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The most valuable and reliable method of diagnosis is the assay of glucocerebrosidase activity in peripheral 
blood leukocytes or cultured fibroblasts(Beutler et al. 1971).  
GD became the first successfully managed lipid storage disease, the cornerstone of treatment for GD, is enzyme 
replacement therapy with a recombinant glucocerebrosidase known as imiglucerase (Cerezyme) which is given 
intravenously (Brady 2006).  
The aim of this study is to determine the DNA Polymorphism of Gaucher Diseases in Iraqi Patient 6 month 
in Children welfare teaching hospital Baghdad- Iraq by using PCR technology.  
 
2- Patients and Methods: 
 
1- A retrospective study conducted on twenty patients admitted to the Gastroenterology and Hepatology 
unit in Children Welfare Teaching Hospital/ medical city complex / Baghdad, their ages were ranged 
between (2-21 years), during the period from the first of May 2013- first December 2013. 
All patients were diagnosed with gaucher disease based upon clinical assessment (detailed history and 
thorough clinical examination), laboratory  investigations(complete blood count (CBC), blood film and 
reticulocyte count, prothrombin time (PT) and partial thromboplastin time (PTT), liver function tests, 
renal function tests, , bone marrow examination (only done in 7 feasible patients),  imaging 
studies included plain X-ray of long bones and chest, abdominal ultrasonography to evaluate liver and 
spleen volumes, echocardiography, and MRI of femurs for selected patients.  And enzymatic 
evaluationby direct determination of (acid beta-glucosidase) activity in peripheral blood leucocytes 
through metabolic laboratory /Hamburg university medical center. 
 
2- Genetic study: 2 ml of blood sample in EDTA tubes were taken from patients, DNA was isolated by 
using Genomic DNA Mini Kit,(Geneaid ,USA). And PCR was 
AccuPower® ProFiTaq PCR PreMix was a suitable lyophilized PCR master mix. 
The primer was  5`-ATCACCAAGCACACGTTTT-3`  (Cormand et al.,1998) 
 
 
Table -1- The Conditions of PCR reaction 
No. Steps Temperature Time Cycles 
1 Initial denaturation 95 °C 5 minutes 1  
2 Denaturation 94 °C 15seconds 30 
3 Annealing 60°C 45 seconds 30 
4 Extension 72 °C 1minute 30 
5 Final extension 72 °C 10 seconds 1  
 
 
4- Results and Discussion: 
 
Of the 20 patients included in this series 15(75%) were males and 5(25%) were females, and the 
commonest age of presentation for the disease was found between 2-5 years in 11 patients, and it accounts (55%) 
it was found that easy tiredness affect all the patients (100%) ,splenomegaly in 80%, hepatomegaly in 75%, 
abdominal pain& bleeding tendency in 70% for each.. 
While the skeletal manifestations presented as bone pain in 55%, as shown in table -2. 
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Table-2 Clinic-epidemiological manifestations of the study sample 
 
Variables Number Percentage 
Gender Male 15 75% 
Female 5 25% 
 
Consanguinity 
Positive 13 65% 
Negative 7 35% 
 
Age group(years) 
1 year - 2 years 4 20% 
>2years- 5 years 11 55% 
>5years- 15 years 4 20% 
>20years 1 5% 
 
 
 
 
 
Clinical presentations 
Easy tiredness    Positive 20 100% 
Negative 0 0% 
Splenomegaly  Positive 16 80% 
Negative           3(+ 1 splenectomized)=4 20% 
Hepatomegaly   Positive 15 75% 
Negative 5 5% 
Bleeding tendency Positive 14   70% 
Negative 6 30% 
Bone pain    Positive 11 55% 
Negative 9 45% 
 
 
Regarding the clinical presentations, it was found that easy tiredness affect all the patients (100%) 
,splenomegaly in 80%, hepatomegaly in 75%, bleeding tendency in 70% . 
 The skeletal manifestations presented as bone pain & short statures in 55%.The hematological situations of the 
patients shows dramatic increment of the platelets count after six months of treatment in 14(70%).With 
hemoglobin level increment in 13(65%) as shown in table-3. 
 
Table-3Clinical and hematological outcomes of patients after six months of initiation the treatment  
 
 
 
 
 
 
 
 
 
 
 
 
Although gaucher disease is the most common lysosomal storage disease all over the world but it still in 
Iraq is thought to be underestimated in part due to unavailability of diagnostic toolsas well as lack of awareness 
with low index of suspicion. 
Out of 20 patients 15 of them were males (75%) and 5 were females (25%) with male to female ratio 3:1and this 
percentage similar to study done by Heitner(Heitner, 2004) in South Africa who revealed 3:1, by Nagral (Nagral 
et al, 2011) in India who showed 3.14:1 and in Albania (Shehi et al, 2011) who showed male to female ratio 
1.75:1. But disagree with results obtained by Giraldoin Iberia (Spain& Portugal) (Giraldo et al., 2012) their ratio 
was about 1:1, and this may be explained by different sample size taken. 
It was found that consanguineous marriage present in 65% of cases which it was quite equal to study done in 
Egypt (Khalifa ,et al,2011) and 50%  in India (Nagral et al., 2011) but this point not submit to great interest in 
other countries which may be due to uneventful percentage of  consanguineous pedigrees. 
 
It was found that the most common age group affected in this study is the first five years of life in three quarter 
of the cases which is closely related to result found in Egypt (Khalifa ,2011),71% in Japan (Eto& Ida ,1999), and 
in 48% in USA (Caplan et al., 2006) and this may be explained by inclusion criteria of the study that involved 
only pediatrics age groups. 
Indices Number Percentage 
Clinical Bleeding tendencyimprovement 20 100% 
Easy tiredness improvement 18 90% 
Splenic regression 17 85% 
Hepatic regression 15 75% 
Hematological Plateletscount increment 14 70% 
Hemoglobin level increment 13 65% 
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Among the clinical manifestations ;Splenomegaly was found in 80% of cases (one case was splenectomized 5%) 
and it is 90.9% (Lee et al., 2012) in Korea  and 95%in USA (Caplan et al., 2006), while in Romania there was 
40%  with splenomegaly and 45% were splenectomized (Drugan et al.,2002). 
 The abdominal pain was present in 70% of cases while it is 81.8% in Albanian children   (Shehi et al, 2011) and 
it is common presentation mostly due to big spleen with its brother some symptoms. 
It was found that hepatomegaly present in 75% of patients while it is 87% in USA (Caplan et al., 
2006)and 100% in Albania (Shehi et al, 2011)  and it is 68% in Iberia (Spain& Portugal) ( Giraldo et al.,2012). 
 
The bleeding tendency(manifested by ecchymosis& epistaxis)  was present in 70% of cases while it is 
27.27%  in Albania (Shehi et al, 2011) and this can be explained by lateness in the diagnosis and treatment of the 
disease until it reach advanced stage. 
Bone pain manifested in 55% of patients, while in France45% of patients had skeletal symptoms (bone 
pain and / or bone crisis) and Korea (Lee et al., 2012), and in Romania the chronic bone pain (65%)(Drugan et 
al., 2002). 
The clear improvement of hematological indices(platelets count  and hemoglobin percentage) were 
obtained after 6months of treatment and this result harmonized with other results in other countries (Weinreb et 
al 2002, Lee et al  2012, Nagral et al 2011). 
The dramatic regressionachievement of hepatosplenomegaly wasagreed with other studies done in other 
countries ( Shehi et al, 2011, Nagral et al., 2011). 
 
The DNA electrophoresis results were shown in the figure (1). In lane1 DNA marker (Lambda DNA\ 
EcoR+ Hind 111) which had 4 bands (21.226, 5.148, 4.268, 2.027bp), lane 2  was normal (control group) had no 
band compare with DNA marker, Lane3-9 were cases with Gaucher disease had one band (21.226) compare with 
DNA marker. The bands were in 7 of 20 patients this mean there is a mutation in glucocerebrosidases gene (G      
C ).   
 
 
   
 
 
 
Figure (1)The DNA electrophoresis of PCR products 
 
The DNA electrophoresis results were shown in the: 
1-  Lane-1- DNA marker (Lambda DNA\ EcoR+ Hind 111) which had 4 bands (21.226, 5.148, 4.268, 
2.027bp). 
2-  Lane- 2-  was normal (control group) had no band compare with DNA marker. 
3- Lane3-9  were cases with Gaucher disease. 
 
 
 
 
1 2           3            4              5            6              7            8           9 
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